GlassScriptPhysician profile
Ehud Zeltzer
NPI 1558100503
$3,474.02
in general payments reported to CMS, 2019-2025
34 companies · $2,919 in 2025
The $2,919 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $556 · 2025: $2,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.04 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.01 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $231.23 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $223.70 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $209.85 | 2025 | Ponvory |
| Biogen, INC. | $190.22 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Acadia Pharmaceuticals INC | $168.13 | 2025 | Nuplazid, Daybue |
| Ucb, INC. | $141.94 | 2024-2025 | Nayzilam, Briviact, Fintepla |
| Tg Therapeutics, INC. | $137.93 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $136.93 | 2024-2025 | Rexulti |
| Argenx US, INC. | $125.51 | 2024-2025 | Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $121.78 | 2024-2025 | Crexont |
| Pfizer INC. | $111.15 | 2025 | |
| Sk Life Science, INC. | $110.35 | 2024-2025 | |
| Emd Serono, INC. | $103.05 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $99.49 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $87.06 | 2025 | Gamunex-C |
| Celgene Corporation | $82.96 | 2025 | Zeposia |
| Tanabe Pharma America, INC. | $73.88 | 2024-2025 | Radicava |
| Ge Healthcare | $73.25 | 2025 | |
| Genentech USA, INC. | $68.09 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $67.99 | 2024-2025 | Ultomiris |
| Axsome Therapeutics, INC. | $62.47 | 2024-2025 | Symbravo, Auvelity |
| Averitas Pharma INC. | $55.09 | 2025 | Qutenza |
| Lilly USA, LLC | $51.05 | 2024-2025 | Kisunla, Emgality |
| Life Molecular Imaging LTD | $40.41 | 2025 | Neuraceq |
| Lundbeck LLC | $35.09 | 2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $33.68 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $32.75 | 2025 | Wainua |
| Cycle Pharmaceuticals INC | $31.99 | 2025 | Tascenso Odt, Bafiertam |
| Janssen Biotech, INC. | $29.57 | 2025 | |
| Microtransponder, INC. | $23.07 | 2025 | |
| Mdd US Operations, LLC | $21.00 | 2024 | Gocovri |
| Novo Nordisk INC | $19.77 | 2025 | |
| Amgen INC. | $16.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehud Zeltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.